Repligen
RGEN
#2379
Rank
A$11.57 B
Marketcap
A$205.17
Share price
2.45%
Change (1 day)
6.29%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of March 2026 : A$0.99 Billion

According to Repligen 's latest financial reports the company's total debt is A$0.99 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31A$1.03 B-6.64%
2024-12-31A$1.10 B5.6%
2023-12-31A$1.04 B68.09%
2022-12-31A$0.62 B23.1%
2021-12-31A$0.50 B40.97%
2020-12-31A$0.35 B-4.76%
2019-12-31A$0.37 B156.02%
2018-12-31A$0.14 B15.55%
2017-12-31A$0.12 B-3.81%
2016-12-31A$0.13 B
2005-03-31A$0.15 M36.5%
2004-03-31A$0.11 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
A$91.82 B 9,168.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
A$62.18 B 6,176.87%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
A$29.21 B 2,848.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$66.89 B 6,651.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
A$36.63 M-96.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
A$0.42 B-57.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
A$0.58 B-40.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
A$0.41 B-57.78%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
A$2.07 B 109.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
A$4.40 B 344.47%๐Ÿ‡บ๐Ÿ‡ธ USA